Hepatitis A: A Clinical Spectrum of the Disease in Children Admitted in a Tertiary Care Hospital
Authors/Creators
- 1. Assistant Professor, Department of Pediatrics, Hind Institute of Medical Sciences, Ataria, Sitapur, Lucknow
- 2. Profeesor (HOD), Department of Pediatrics, K.G.M.U, Lucknow
Description
Abstract:
Introduction: HAV causes acute hepatitis worldwide, mostly through oral-faecal pathways. While rich nations
have lower infection rates, injection drug users, men who have sex with males, travellers to endemic areas, and
secluded populations are at risk. HAV doesn't cause chronic liver illness like hepatitis B or C. Children over 12
months should be vaccinated. Poor sanitation causes high endemic rates in impoverished countries.
Aims and Objectives: This study aims to examine the clinical spectrum of Hepatitis A in paediatric patients.
Method: The Paediatric Department of Hind Medical College Ataria, Sitapur conducted this cross-sectional study
from February 2022, to February, 2023, to investigate acute hepatitis in children aged 1-12. The Institutional
Ethical Review Board approval had been taken for the study, excluding children with preexisting liver disease and
including those with acute hepatitis symptoms lasting ≤21 days, high ALT, and parental agreement. Demographics, clinical symptoms, ELISA blood samples for anti-HAV and anti-HEV IgM antibodies, and laboratory
data were collected.
Results: Table 1 shows 150 youngsters with HAV-induced acute viral hepatitis. The average age was 7.3±3.0
years, with 42% aged 6-10 years. Male patients made up 53.33% and rural residents 55.33%. Maternal education
varied, and 36.66% were lower-middle-class. Table 2 lists HAV-related symptoms including fever (72.66%),
jaundice (65.33%), and black urine (70.00%). Table 3 shows increased bilirubin, ALT, AST, ALP, and INR,
emphasizing the necessity for early medical intervention in acute HAV patients.
Conclusion: The majority of HAV-induced acute viral hepatitis cases occur in 6-10-year-olds, highlighting the
need for routine immunisation and public health education.
Abstract (English)
Abstract:
Introduction: HAV causes acute hepatitis worldwide, mostly through oral-faecal pathways. While rich nations
have lower infection rates, injection drug users, men who have sex with males, travellers to endemic areas, and
secluded populations are at risk. HAV doesn't cause chronic liver illness like hepatitis B or C. Children over 12
months should be vaccinated. Poor sanitation causes high endemic rates in impoverished countries.
Aims and Objectives: This study aims to examine the clinical spectrum of Hepatitis A in paediatric patients.
Method: The Paediatric Department of Hind Medical College Ataria, Sitapur conducted this cross-sectional study
from February 2022, to February, 2023, to investigate acute hepatitis in children aged 1-12. The Institutional
Ethical Review Board approval had been taken for the study, excluding children with preexisting liver disease and
including those with acute hepatitis symptoms lasting ≤21 days, high ALT, and parental agreement. Demographics, clinical symptoms, ELISA blood samples for anti-HAV and anti-HEV IgM antibodies, and laboratory
data were collected.
Results: Table 1 shows 150 youngsters with HAV-induced acute viral hepatitis. The average age was 7.3±3.0
years, with 42% aged 6-10 years. Male patients made up 53.33% and rural residents 55.33%. Maternal education
varied, and 36.66% were lower-middle-class. Table 2 lists HAV-related symptoms including fever (72.66%),
jaundice (65.33%), and black urine (70.00%). Table 3 shows increased bilirubin, ALT, AST, ALP, and INR,
emphasizing the necessity for early medical intervention in acute HAV patients.
Conclusion: The majority of HAV-induced acute viral hepatitis cases occur in 6-10-year-olds, highlighting the
need for routine immunisation and public health education.
Files
IJCPR,Vol15,Issue10,Article54.pdf
Files
(341.3 kB)
| Name | Size | Download all |
|---|---|---|
|
md5:69dcd822a3abb068498513b2f3693258
|
341.3 kB | Preview Download |
Additional details
Dates
- Accepted
-
2023-10-10